Objetivo Malaria is a serious parasitic disease afflicting 198 million people in 2013, with an estimated death toll of approximately 600 000. Approximately half the world’s population is at risk of malaria. So far there is no cure/vaccine against malaria and current chemoprotective treatments have shortcomings, such as: 1) Limited Number of Drugs effective against malaria parasites; 2) Adverse Side Effects (observed in 32% to 44% of users); 3) Parasite Resistance to most of the drugs used for prevention and treatment; and 4) Limited Use (restrictions on age, genetic traits, pregnancy, etc). Our ERC-funded research uncovered a novel mechanism of action that can be targeted for malaria chemoprotection, with fewer side effects and reduced propensity to generate parasite resistance, on which we filed for IP protection. Furthermore, we have identified a set of likely drug candidates already validated in the clinic, which are likely candidates for malaria chemoprotection. In fact, our preliminary data indicates that a known anti-diabetic drug significantly affects parasite growth. We are seeking funding to initiate pre-clinical studies for repurposing this drug for malaria chemoprotection. This PoC funding will allow us to complete the following aims: 1) in vitro profiling to define therapeutic dose for malaria chemoprotection; 2) in vivo profiling to perform efficacy and toxicity studies; 3) further define IP Strategy; 4) draft early stage Regulatory Approval Roadmap; 5) conduct Market Analysis and develop a Business Case. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth sciencesinfectious diseasesmalariamedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesclinical medicineobstetrics Programa(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Tema(s) ERC-PoC-2015 - ERC Proof of Concept Grant Convocatoria de propuestas ERC-2015-PoC Consulte otros proyectos de esta convocatoria Régimen de financiación ERC-POC - Proof of Concept Grant Institución de acogida INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES Aportación neta de la UEn € 145 500,00 Dirección AVENIDA PROF EGAS MONIZ 1649 028 Lisboa Portugal Ver en el mapa Región Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa Tipo de actividad Research Organisations Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 145 500,00 Beneficiarios (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES Portugal Aportación neta de la UEn € 145 500,00 Dirección AVENIDA PROF EGAS MONIZ 1649 028 Lisboa Ver en el mapa Región Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa Tipo de actividad Research Organisations Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 145 500,00